Based at BioArk TechPark in Monthey and supported by the incubation program of the Foundation The Ark, Bioscibex has been selected among the 60 semi-finalists of the 2026 >>venture>> competition.
Organized annually, >>venture>> is one of Switzerland’s largest startup competitions, attracting several hundred applications each year across multiple sectors. The selection of Bioscibex marks the first stage of a multi-step evaluation process.
A step-by-step selection process
The >>venture>> competition is structured in several phases:
- An initial review of applications and eligibility
- Allocation to expert reviewers
- A first jury round selecting 60 semi-finalists
- A mentoring and coaching phase for selected teams
- A second jury round leading to 18 finalists
- A final pitch and award ceremony
Following its selection, Bioscibex will now enter the mentoring and coaching phase, where semi-finalists refine their strategy and presentation with the support of experts, ahead of the next jury round.
Advancing innovation in bioproduction
Bioscibex is developing a machine designed to improve the production of monoclonal antibodies. The technology aims to make manufacturing processes faster, more cost-effective, and safer compared to existing methods.
Monoclonal antibodies play a central role in many therapeutic areas, including oncology and autoimmune diseases. Innovations in their production are therefore a key topic within the biopharmaceutical industry.
A recognition within the Swiss startup ecosystem
Being selected as a semi-finalist reflects both the quality of the project and its potential relevance for the life sciences sector.
The upcoming stages of the competition will further assess projects through expert evaluation and pitching sessions, leading to the final selection of winners in June.
Further information
More information about the competition and the list of semi-finalists:
https://www.venture.ch/semi-finalists-2026
About Bioscibex:
https://www.bioscibex.com/
